Health SystemsHelix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse PopulationsNovember 13, 2024
Published ResearchA novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohortNovember 4, 2024
Published ResearchInfluence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studyNovember 3, 2024
Health SystemsHelix to Showcase the Impact of Clinico-Genomic Research on Clinical Care and Drug Discovery at ASHG Annual MeetingOctober 30, 2024
Life SciencesHelix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic DataJune 24, 2024
Life SciencesHelix Launches Clinico-Genomic Datasets for Cardiovascular, Metabolic, Immunology and Inflammation DisordersJune 7, 2024
Life SciencesUnleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic developmentApril 5, 2024
Life SciencesUnraveling the Power of Germline Clinico-Genomic Data: A Game Changer in Pharma's Drug Development LifecycleMarch 19, 2024
Life SciencesHelix appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life SciencesMarch 19, 2024
Public HealthPreventable hospitalizations with increased oral SARS-CoV-2 antiviral treatmentFebruary 5, 2024
Public HealthInsights from IDWeek 2023: Viral SARS-CoV-2 rebound in untreated and anti-viral treated patientsDecember 4, 2023
Life SciencesMayo Clinic Laboratories and Helix collaborate to provide comprehensive suite of laboratory services to biopharma customersJanuary 9, 2023
Helix PartnersHelix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary DiseasesJanuary 5, 2023